All In Biotech

Drug Trial Radar · NCT07176650

Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

A Randomized, Multicenter, Double-Blind, Parallel-Controlled, Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

Last checked: Nov 19, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 246 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

246

Planned (sponsor's estimate)

Start

Nov 25, 2025

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Shanghai Henlius BiotechIndustry
Sponsor type
Industry
First posted
Sep 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, parallel-controlled, phase I clinical study to evaluate the PK characteristics, safety, efficacy, and immunogenicity of HLX13 and US-sourced YERVOY® in patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

Conditions

  • Hepatocellular Carcinoma (HCC)

Interventions

  • HLX13Drug

    Patients will receive HLX13 (3 mg/kg) treatment on the first day of each 3-week cycle, up to 4 cycles.

  • YervoyDrug

    Patients will receive US-sourced YERVOY® (3 mg/kg) treatment on the first day of each 3-week cycle, up to 4 cycles.

  • OPDIVODrug

    Patients will receive EU-sourced OPDIVO® (EU-sourced nivolumab) (1 mg/kg) treatment on the first day of each 3-week cycle, up to 4 cycles. Subjects who may continue to benefit from OPDIVO® treatment as assessed by investigators will be subsequently treated with local-sourced OPDIVO® monotherapy every 4 weeks, up to 2 year after randomization.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the serum concentration-time curve from time 0 to 21 days (AUC0-21d) after the 1st doseTime frame: from time 0 to 21 days after the 1st dose (3 weeks)
  2. Area under the serum concentration-time curve within a dosing interval at steady-state (AUCss) after the 4th doseTime frame: from time 0 to 78 days after the 4th dose (20 weeks)

Locations

51 sites in 2 countries. Site status is shown where the registry gives one.

  • Oncology Physicians Network (OPN) - Los Alamitos /OPN Healthcare

    Glendale, California · Recruiting

  • Los Angeles Cancer Network

    Glendale, California · Not yet recruiting

  • Cancer Specialists of North Florida

    Jacksonville, Florida · Not yet recruiting

  • D&H National Research Centers, LLC

    Margate, Florida · Recruiting

  • Mid Florida Hematology and oncology Center

    Orange City, Florida · Recruiting

  • Florida Clinical Trials Group

    Plantation, Florida · Not yet recruiting

  • Florida Clinical Trials Group

    Tamarac, Florida · Not yet recruiting

  • HCA Research Institute, LLC

    Brentwood, Tennessee · Not yet recruiting

  • Oncology Consultants

    Houston, Texas · Recruiting

  • American Oncology Network Vista Oncology Division/Physician Partner Associate

    Olympia, Washington · Recruiting

  • Northwest Medical Specialties PLLC (NWMS)

    Tacoma, Washington · Recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, China · Recruiting

  • Peking Union Medical College Hospital

    Beijing, China · Recruiting

  • Peking university international hospital

    Beijing, China · Recruiting

  • The First Affiliated Hospital of Bengbu Medical University

    Bengbu, China · Recruiting

  • JiLin Cancer Hospital

    Changchun, China · Recruiting

  • The First Hospital of Jilin University

    Changchun, China · Recruiting

  • People's Hospital of Hunan Province

    Changsha, China · Recruiting

  • Chengdu Fifth People's Hospital

    Chengdu, China · Recruiting

  • Sichuan Cancer Hospital

    Chengdu, China · Recruiting

  • Dongguan People's Hospital

    Dongguan, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, China · Recruiting

  • Ganzhou People's Hospital

    Ganzhou, China · Recruiting

  • Nanfang Hospital, Southern Medical University

    Guangzhou, China · Recruiting

  • Hainan General Hospital

    Haikou, China · Recruiting

  • Sir Run Run Shaw Hospital Affiliated with Zhejiang University School of Medicine

    Hangzhou, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, China · Recruiting

  • The First Affiliated Hospital of USTC (Anhui Provincial Hospital)

    Hefei, China · Recruiting

  • Jinan Central Hospital

    Jinan, China · Recruiting

  • Affiliated Hospital of Jining Medical University

    Jining, China · Recruiting

  • Linyi Cancer Hospital

    Linyi, China · Recruiting

  • Lishui Central Hospital

    Lishui, China · Recruiting

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, China · Recruiting

  • Jiangxi Cancer Hospital

    Nanchang, China · Recruiting

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, China · Recruiting

  • Jiangsu Province Hospital

    Nanjing, China · Recruiting

  • The Affiliated Hospital of Nanjing university Medical School

    Nanjing, China · Recruiting

  • Guangxi Medical University Cancer Hospital

    Nanning, China · Recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, China · Recruiting

  • Shanghai Gobroad Cancer Hospital

    Shanghai, China · Recruiting

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.